Market Flux Event
Amgen and AstraZeneca Drug Combo Cuts Death Risk by 58% in Aggressive Lung Cancer Trial
Read this in the Market Flux appA combination of Amgen's Imdelltra and AstraZeneca's Imfinzi reduced the risk of death by 58% in patients with first-line extensive-stage small cell lung cancer, one of the most aggressive and difficult-to-treat forms of the disease, according to trial data presented at the ESMO oncology congress.
Nearly 80% of patients receiving the Imdelltra-Imfinzi combination were alive at one year, compared with 53% of patients treated with durvalumab, the AstraZeneca immunotherapy, alone. Progression-free survival was more than tripled in the combination arm relative to the control group.
The results were presented at the European Society for Medical Oncology meeting, a major oncology conference running October 23 to 27, 2026. The findings reinforce the potential for combining Amgen's bispecific T-cell engager Imdelltra with checkpoint immunotherapy as a first-line treatment standard in a cancer type that has historically offered patients limited survival options.
© AI-generated summary is provided by Market Flux
Sources
- CnbcAmgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- FirstSquawkAMGEN SAYS NEARLY 80% OF PATIENTS ON IMDELLTRA-IMFINZI WERE ALIVE AT ONE YEAR VERSUS 53% WITH DURVALUMAB ALONE, WITH PROGRESSION-FREE SURVIVAL MORE THAN TRIPLED, AND THAT THE COMBINATION REDUCED THE RISK OF DEATH BY 58% IN FIRST-LINE EXTENSIVE-STAGE SMALL CELL LUNG CANCER
- ReutersAmgen drug combined with immunotherapy extends survival in lung cancer trial
- BusinessA combination of powerful Amgen and AstraZeneca drugs helped patients with an aggressive form of lung cancer to live longer, data presented at the ESMO oncology meeting showed.